Literature DB >> 3070148

Immunosuppressant therapy of thyroid eye disease.

G Kahaly1, J Beyer.   

Abstract

Thyroid eye disease is attributed to an autoimmune process where both cellular and humoral immunity play a role. In this report, after a short introduction dealing with immunopathogenesis of the disease, immunosuppressant therapy is discussed. Treatment with glucocorticoids (as the standard substance), nonsteroid immunosuppressants (azathioprine, cyclophosphamide, lately cyclosporin) and with the immunomodulatory substance ciamexone is reviewed. Retroorbital irradiation as a "local" immunosuppressive method and plasmapheresis are also discussed. While systemic glucocorticoids and to a lesser extent orbital radiotherapy are routinely administered for severe Graves' ophthalmopathy, nonsteroid immunosuppressants and plasmapheresis are not yet part of the established treatment of thyroid eye disease. Their use should currently remain confined to controlled studies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3070148     DOI: 10.1007/bf01711917

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  60 in total

1.  Immunosuppressive therapy for the eye changes of Graves' disease.

Authors:  G N Burrow; M S Mitchell; R O Howard; L B Morrow
Journal:  J Clin Endocrinol Metab       Date:  1970-09       Impact factor: 5.958

2.  Corticosteroids in the treatment of optic nerve involvement associated with thyroid dysfunction.

Authors:  R M Day; F D Carroll
Journal:  Arch Ophthalmol       Date:  1968-03

3.  [The course of endocrine ophthalmopathy and effectiveness of established therapeutic measures].

Authors:  E Schifferdecker; F Schulz; C Rosak; P H Althoff
Journal:  Med Klin (Munich)       Date:  1986-11-21

4.  Graves' disease and HLA: clinical and epidemiologic associations.

Authors:  N R Farid; E Stone; G Johnson
Journal:  Clin Endocrinol (Oxf)       Date:  1980-12       Impact factor: 3.478

5.  Changes in thyroid functions in patients with euthyroid Graves' disease.

Authors:  H Tamai; T Nakagawa; N Ohsako; O Fukino; H Takahashi; F Matsuzuka; K Kuma; S Nagataki
Journal:  J Clin Endocrinol Metab       Date:  1980-01       Impact factor: 5.958

6.  Delayed hypersensitivity in Graves' disease and exophthalmos: identification of thyroglobulin in normal human orbital muscle.

Authors:  B R Mullin; R E Levinson; A Friedman; D E Henson; R J Winand; L D Kohn
Journal:  Endocrinology       Date:  1977-02       Impact factor: 4.736

7.  Graves's disease and total thyroidectomy. Progression of severe eye changes and decrease in serum long acting thyroid stimulator after operation.

Authors:  S C Werner; C R Feind; M Aida
Journal:  N Engl J Med       Date:  1967-01-19       Impact factor: 91.245

8.  The pathogenesis of Graves' ophthalmopathy.

Authors:  P Kendall-Taylor
Journal:  Clin Endocrinol Metab       Date:  1985-05

9.  Monoclonal antibody studies defining the origin and properties of autoantibodies in Graves' disease.

Authors:  L D Kohn; F Alvarez; C Marcocci; A D Kohn; D Corda; W E Hoffman; D Tombaccini; W A Valente; M de Luca; P Santisteban
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

10.  Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy.

Authors:  P W Wang; Y Hiromatsu; E Laryea; L Wosu; J How; J R Wall
Journal:  J Clin Endocrinol Metab       Date:  1986-08       Impact factor: 5.958

View more
  2 in total

1.  Long-term observation of endocrine ophthalmopathy and retrospective appraisal of therapeutic measures.

Authors:  G Kahaly; H Böckmann; J Beyer; S Bischoff
Journal:  J Endocrinol Invest       Date:  1990-04       Impact factor: 4.256

2.  Diagnosis, Follow-Up and Treatment Results in Thyroid Ophthalmopathy.

Authors:  Esra Savku; Kaan Gündüz
Journal:  Turk J Ophthalmol       Date:  2015-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.